Feds Propose New Fertility Benefits Category, Capping IVF Coverage at $120,000

Why It Matters

The proposal gives companies a flexible, low‑risk way to meet growing employee demand for fertility care, potentially expanding access for millions while limiting regulatory and cost exposure.

Key Takeaways

• New “limited excepted” category isolates IVF from standard health plan rules
• Lifetime cap set at $120,000, indexed for medical inflation after 2027
• Up to 54 million workers could enroll, with 743k expected annually
• Employers can design benefit without mandatory contributions or minimum coverage
• Self‑insured plans gain broadest relief; state mandates may not apply

Pulse Analysis

Fertility benefits have moved from a niche perk to a mainstream expectation as more workers delay childbearing and seek assisted‑reproductive technologies. A single IVF cycle can cost $15,000‑$20,000, and many families require multiple attempts, pushing total expenses well beyond $40,000. Yet only about a quarter of large employers currently offer any IVF coverage, leaving a sizable gap that fuels employee dissatisfaction and talent‑retention challenges. The new rule, rooted in Executive Order 14216, seeks to close that gap by creating a distinct benefit class that sidesteps the complex compliance landscape of traditional group health plans.

Under the proposed framework, employers may package diagnostics, medications, and IVF procedures into a separate limited excepted benefit, subject to a $120,000 lifetime cap that will be indexed for medical inflation after plan years beginning in 2027. The exemption mirrors existing carve‑outs for dental, vision and long‑term care, allowing plan sponsors to tailor contribution levels, eligibility criteria and provider networks without triggering ACA or ERISA mandates. Self‑insured carriers stand to gain the most, as state IVF mandates typically do not apply to them, potentially unlocking coverage for over half of the private‑sector workforce. Fully insured plans in mandate states may still face state‑level requirements, creating a nuanced compliance landscape.

For HR leaders, the rule presents strategic choices: whether to launch a new fertility offering, migrate existing coverage into the excepted bucket, or simply observe market uptake. Budgeting must account for adverse selection, as employees may time enrollment around treatment needs. The agencies have opened a comment period until July 13, 2026, inviting feedback on take‑up assumptions and cap structures. If finalized, the rule could reshape benefits portfolios, drive competitive differentiation, and expand access to life‑changing reproductive care for millions of American workers.